Tseng-Hui T Chen

发表

In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma

M. Srinivasan, R. Graziano, D. King, 2009, Clinical Cancer Research.

CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.

Yi-hong Wang, D. King, G. Yarranton, 2003, Cancer research.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2015, The Journal of clinical investigation.

Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors

A. Korman, K. Jooss, M. Vanroey, 2009, Clinical Cancer Research.

CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager

R. Dubridge, P. Culp, Tseng-Hui T Chen, 2022, Biochemistry and biophysics reports.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors

Jeremiah D. Degenhardt, Danielle E. Dettling, R. Dubridge, 2020, mAbs.

Anticorps contre tigit

M. Srinivasan, P. Sheppard, D. Ardourel, 2015 .

CD 10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004 Na and Novel Analogues : Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD 10 Tumors

Yi-hong Wang, D. King, G. Yarranton, 2003 .

In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma

M. Srinivasan, R. Graziano, D. King, 2009, Clinical Cancer Research.